OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
The product will be manufactured at Lupin’s Nagpur facility in India
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Yesafili, received marketing authorization approval from the European Commission for the European Union
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
he company posted total income during Q2 FY24 at Rs. 12.86 crore
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Subscribe To Our Newsletter & Stay Updated
